Liftopram EZ Tablet contains a combination of Etizolam (0.5 mg) and Escitalopram Oxalate (10 mg), formulated to manage anxiety disorders and depressive symptoms. Etizolam, a thienodiazepine derivative, exhibits anxiolytic, sedative, and muscle-relaxant properties by modulating the gamma-aminobutyric acid (GABA) receptor complex, thereby producing a calming effect on the central nervous system. Escitalopram Oxalate, a selective serotonin reuptake inhibitor (SSRI), enhances serotonergic neurotransmission by inhibiting the reuptake of serotonin in the synaptic cleft, which helps alleviate depressive symptoms and improve mood. The combined action of these agents provides symptomatic relief in patients experiencing generalized anxiety disorder, panic disorder, and major depressive disorder. Liftopram EZ is indicated for short to medium-term use under medical supervision, with careful monitoring for potential side effects such as drowsiness, dizziness, gastrointestinal disturbances, and the risk of dependence associated with Etizolam. Caution is advised in patients with hepatic or renal impairment, and it should not be combined with other central nervous system depressants or alcohol. Dosage and duration of therapy should be individualized based on clinical response and tolerability, ensuring optimal therapeutic outcomes while minimizing adverse effects.